![]() |
|
|
Vol. 29, Issue 12, 1629-1637, December 2001
Human BioMolecular Research Institute, San Diego, California
(J.R.C., J.Z.); and Sequenom Incorporated, San Diego, California (J.L.,
A.B.)
The N-oxygenation of amines by the human
flavin-containing monooxygenase (form 3) (FMO3) represents an important
means for the conversion of lipophilic nucleophilic
heteroatom-containing compounds into more polar and readily excreted
products. Certain mutations of the human FMO3 gene have
been linked to abnormal drug or chemical metabolism. For example,
abnormal N-oxygenation of trimethylamine has been shown
to segregate with mutations of human FMO3. To date,
however, it is not known whether there is a pharmacogenetic basis for
abnormal drug metabolism by human FMO3. The objective of
this study was to estimate the allele and genotype frequencies at three
variable DNA sites in the FMO3 gene in male and female
blood bank donors representative of non-Hispanic Caucasians,
non-Hispanic African Americans, Hispanics, and Asians sampled from the
United States. The common polymorphisms at variable sites 158, 257, and
308 were experimentally determined using a high-throughput chip-based
genotype variation detection method combining MassEXTEND and
matrix-assisted laser desorption ionization time-of-flight mass
spectrometry. We also compared the genetic variation of nonhuman
primate FMO3 with the human FMO3 gene.
Exon sequence analysis of the monkey FMO3 gene sequence
showed that it was similar to the human gene sequence but differed from
the human consensus sequence at 31 fixed positions. Compared with that
of human, the chimpanzee exon sequence had one polymorphism that
induced an amino acid change. The evolutionary history of the
FMO3 gene was inferred from the pattern of haplotype
relationships across different populations and species. Statistically
significant heterogeneity in the relative frequencies of single and
multiple site alleles, haplotypes, and genotypes of the human
FMO3 among ethnic subdivisions suggests that population
differences in the susceptibility of humans to abnormal metabolism or
adverse drug reactions for chemicals metabolized by human FMO3 could exist.
This article has been cited by other articles:
![]() |
M. Shimizu, H. Yano, S. Nagashima, N. Murayama, J. Zhang, J. R. Cashman, and H. Yamazaki Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on N- and S-Oxygenation Activities Drug Metab. Dispos., March 1, 2007; 35(3): 328 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Koukouritaki, M. T. Poch, M. C. Henderson, L. K. Siddens, S. K. Krueger, J. E. VanDyke, D. E. Williams, N. M. Pajewski, T. Wang, and R. N. Hines Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 266 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Borbas, J. Zhang, M. A. Cerny, I. Liko, and J. R. Cashman Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3 Drug Metab. Dispos., December 1, 2006; 34(12): 1995 - 2002. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bain, R. Faull, G. Fornasini, R. W. Milne, and A. M. Evans Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1300 - 1304. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Hisamuddin, M. A. Wehbi, A. Chao, H. W. Wyre, L. M. Hylind, F. M. Giardiello, and V. W. Yang Genetic Polymorphisms of Human Flavin Monooxygenase 3 in Sulindac-Mediated Primary Chemoprevention of Familial Adenomatous Polyposis Clin. Cancer Res., December 15, 2004; 10(24): 8357 - 8362. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Hines, Z. Luo, K. A. Hopp, E. T. Cabacungan, S. B. Koukouritaki, and D. G. McCarver Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6) J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1210 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lattard, J. Zhang, Q. Tran, B. Furnes, D. Schlenk, and J. R. Cashman TWO NEW POLYMORPHISMS OF THE FMO3 GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIES Drug Metab. Dispos., July 1, 2003; 31(7): 854 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Furnes, J. Feng, S. S. Sommer, and D. Schlenk Identification of Novel Variants of the Flavin-Containing Monooxygenase Gene Family in African Americans Drug Metab. Dispos., February 1, 2003; 31(2): 187 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cashman and J. Zhang Interindividual Differences of Human Flavin-Containing Monooxygenase 3: Genetic Polymorphisms and Functional Variation Drug Metab. Dispos., October 1, 2002; 30(10): 1043 - 1052. [Abstract] [Full Text] [PDF] |
||||